Skip to content
Clinical Trials – home

Casa della Salute

Research site

Italy Borgo Santa Lucia 52, 03023 Ceccano, Italy

  • 1 trial recruiting
  • Arteriosclerosis · Type 2 diabetes mellitus
  • Adult patients

About Specializations

Casa della Salute in Ceccano, Italy specialises in clinical trials of conditions such as Arteriosclerosis, Type 2 diabetes mellitus, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular and Metabolic Research

At Casa della Salute in Ceccano, clinical research focuses on the intersection of cardiovascular diseases and nutritional and metabolic diseases, with studies centered on common conditions that strongly affect long-term health.

  • Research on atherosclerotic cardiovascular disease and overweight or obesity, aimed at understanding whether a new treatment can better lower cardiovascular risk and improve outcomes.
  • Clinical evaluation of type 2 diabetes, with a focus on improving blood sugar control in people whose condition is not adequately managed with current therapy.

These trials are designed to test whether emerging therapies can improve glycaemic control and reduce serious cardiovascular events, supporting better care for patients with chronic metabolic and heart-related disease.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Borgo Santa Lucia 5203023 CeccanoItaly
Recruiting now
1 trial
Conditions studied
2

More sites in CeccanoItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

2 clinical trials

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Study on the Effectiveness of Weekly IcoSema (Insulin Icodec and Semaglutide) vs. Daily Insulin Glargine for Adults with Type 2 Diabetes Not Controlled by Oral Drugs

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Novo Nordisk A/S
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.